Valuation: Outlook Therapeutics, Inc.

Market Cap 190M 166M 153M 141M 268M 18.1B 273M 1.83B 718M 8.92B 712M 697M 30.65B P/E 2026 *
-3.2x
P/E 2027 * -5.23x
Enterprise Value 190M 166M 153M 141M 268M 18.1B 273M 1.83B 718M 8.92B 712M 697M 30.65B EV / Sales 2026 *
158x
EV / Sales 2027 * 4.15x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day-6.55%
1 week+8.28%
Current month-1.26%
1 month+42.73%
3 months+530.52%
6 months+166.10%
Current year-0.63%
1 week 1.3
Extreme 1.3
1.87
1 month 1.13
Extreme 1.13
1.88
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
02/06Buy

Director

29,000 0.0181%
28/05
Gms Ventures & Investments
BuyCompany 39,516,849 24.6751%
27/05Buy

Chairman

122,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
-6.55%+8.28%-24.15%-95.46% 190M
+0.58%+2.06%+3.90%+10.40% 50.73B
-2.22%-1.25%+391.53%+591.38% 39.73B
-0.54%+0.39%+27.67%-3.89% 34.69B
-1.36%+0.35%+19.34%+58.83% 33.21B
+1.21%-4.58%+3.00%+37.03% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+125.61% 15.37B
+0.23%-0.58%+13.80%+19.56% 13.78B
-0.62%-3.09%+11.43%-29.93% 12.85B
Average -1.06%+0.08%+56.99%+79.28% 24.41B
Weighted average by Cap. -0.49%-0.23%+82.66%+125.96%

Financials

2026 *2027 *
Net sales 1.2M 1.05M 968K 894K 1.7M 114M 1.73M 11.57M 4.54M 56.38M 4.51M 4.41M 194M 45.73M 40M 36.89M 34.07M 64.66M 4.36B 65.74M 441M 173M 2.15B 172M 168M 7.39B
Net income -52.18M -45.64M -42.1M -38.88M -73.78M -4.98B -75.02M -503M -198M -2.45B -196M -192M -8.43B -42.33M -37.03M -34.15M -31.54M -59.85M -4.04B -60.86M -408M -160M -1.99B -159M -155M -6.84B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
10/07/26 USD 1.570 -6.55% 7,349,600
09/07/26 USD 1.680 -0.59% 10,431,113
08/07/26 USD 1.690 +15.75% 12,542,793
07/07/26 USD 1.460 +2.82% 4,761,647
06/07/26 USD 1.420 -2.07% 7,353,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.570USD
Average target price
5.500USD
Spread / Average Target
+250.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock